Anteris Technologies Welcomes New Board Members for Growth
ANteris Technologies Global Corp., a prominent global player in the structural heart market, recently made significant strides in its leadership. The company is excited to announce the appointments of David Roberts and Gregory Moss to its Board of Directors. This move comes at a crucial time as the company gears up to launch its pivotal DurAVR THV global clinical trial, marking a critical step in its growth strategy.
Strategic Appointments to Enhance Leadership
John Seaberg, Chairman of Anteris Technologies, expressed enthusiasm regarding the new additions to the board. "We are thrilled to welcome David and Gregory to our team," he stated. With their vast experience in the healthcare sector, they will play pivotal roles as the company transitions into this exciting next phase following its recent NASDAQ listing. Furthermore, Seaberg thanked Dr. Wenyi Gu for his valuable contributions and commitment to the company during his tenure.
Profiles of the New Board Members
David Roberts
Mr. David Roberts brings a wealth of experience in the medical device industry. Currently serving as President of LeMaitre Vascular, Inc., he has been with the company since 1997 and has held key positions that shaped its growth trajectory. His tenure at LeMaitre includes significant roles such as Chief Financial Officer and Vice President of Business Development. David has a robust academic background, holding a Bachelor of Arts from Brown University and an MBA from Stanford University. He also serves on the board of multiple medical companies, emphasizing his influence in healthcare.
Gregory Moss
Mr. Gregory Moss is a seasoned legal and business executive, currently the Chief Business and Legal Officer at Evommune, Inc. His prior experience includes a notable role at Kadmon, where he managed legal affairs and compliance, contributing to a major acquisition in the healthcare sector. Gregory’s diverse background in law—as both a solicitor and corporate counsel—equips him with the skills necessary to guide Anteris through its upcoming challenges and opportunities. He is well-educated, with degrees from Macquarie University, and maintains active memberships with several legal associations.
Looking Ahead: The PARADIGM Trial
As David Roberts and Gregory Moss step into their roles, both men will be instrumental in navigating Anteris Technologies through the upcoming global pivotal PARADIGM study, scheduled for the third quarter of 2025. This study aims to secure licensure for the DurAVR THV in the U.S. and the European Medicines Agency (EMA), which will be crucial for bringing innovative heart solutions to patients suffering from aortic stenosis.
About Anteris Technologies
Anteris Technologies Global Corp. is dedicated to the creation and development of innovative medical devices aimed at restoring heart functionality. Founded in Australia, the company has expanded its operations across key markets, including a strong presence in the U.S. Even more importantly, Anteris focuses heavily on research and development, utilizing a team of experts to address various structural heart diseases.
The company's flagship product, the DurAVR THV, represents a significant advancement in treating aortic stenosis. Collaborating with leading cardiac professionals, Anteris designed this transcatheter heart valve, which utilizes patented ADAPT tissue technology. This innovation has already been FDA-approved and demonstrates significant clinical success, providing treatment to over 55,000 patients worldwide.
Connecting with Us
For additional inquiries or deeper engagement regarding Anteris Technologies, potential investors and interested parties can reach out to the company's Investor Relations team. Contact Debbie Ormsby for general inquiries and Malini Chatterjee, Ph.D., for U.S. market-related questions. You can also stay connected with us through our website and social media platforms for the latest updates on our innovations and progress.
Frequently Asked Questions
What is the role of David Roberts at Anteris Technologies?
David Roberts has been appointed to the Board of Directors and brings extensive experience from his role as President of LeMaitre Vascular, Inc.
What is the significance of the PARADIGM Trial?
The PARADIGM Trial is crucial for gaining licensure for the DurAVR THV, facilitating its introduction to the U.S. and EMA markets.
What are Anteris Technologies’ main products?
Anteris Technologies primarily focuses on the DurAVR THV, designed to treat aortic stenosis through advanced tissue technology.
How can I contact Anteris Technologies for investor relations?
You can reach the Investor Relations team at Anteris for inquiries by emailing investor@anteristech.com.
Where can I find more information about Anteris Technologies?
Additional information is available on the company’s website at www.anteristech.com.
